Targets › RYR2
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Jun 2027.
Cytosolic calcium-activated calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytosol and thereby plays a key role in triggering cardiac muscle contraction. Aberrant channel activation can lead to cardiac arrhythmia. (UniProt, Q92736)
Open in Phaseline: the race on RYR2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Solid Biosciences | SGT-501 Gene therapy for ryanodine receptor 2 (RYR2) deficiency | RYR2 | Phase 1 | Catecholaminergic Polymorphic Ventricular Tachycardia | Jun 2027 |
Catecholaminergic Polymorphic Ventricular Tachycardia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.